mp.weixin.qq.com·· 19 hours agoPickScore66
2026 ESMO: ECLYPse, TRIDENTE and BRICKET Test Post-Targeted-Therapy Strategies in BRAF V600E-Mutant mCRC, ctDNA-Guided Retreatment Shows No Objective Responses
In brief
At ESMO 2026, three phase II studies of post-targeted-therapy strategies in BRAF V600E-mutant metastatic colorectal cancer (mCRC) were presented: ECLYPse met its primary endpoint, TRIDENTE showed clinical activity, and BRICKET observed no objective responses.
Why it matters
The three studies compare different post-EC-progression strategies in the same molecular subtype, with efficacy and ctDNA stratification data that can be compared, and BRICKET's negative result provides an exclusionary clue.
Source: mp.weixin.qq.com · mp.weixin.qq.com